Mark Roithmayr (@theaddfceo) 's Twitter Profile
Mark Roithmayr

@theaddfceo

Proudly stewarding the @theADDF to solve for #Alzheimers. Husband, Father and Grandpa. Arsenal enthusiast. Opinions are my own.

ID: 1800922843351302144

linkhttp://alzdiscovery.org calendar_today12-06-2024 16:07:32

32 Tweet

81 Followers

296 Following

Mark Roithmayr (@theaddfceo) 's Twitter Profile Photo

The ā€˜Times they are a changingā€¦ā€ So great to see Eli Lilly and Company and Eisai U.S. Neurology along with novel therapeutics pioneers Howard Fillit, MD and Jeffrey Cummings joined by AD statistical expert Suzanne Hendrix opening the door to combination therapies in Alzheimer’s!

Mark Roithmayr (@theaddfceo) 's Twitter Profile Photo

MSM has been writing a lot lately on Alzheimer’s. Unfortunately it has been a backwards look, stirring up a long decided ago debate on the amyloid theory. Nice to see Pharma Boardroom provide a clear view on truly where we are, and where we are headed. pharmaboardroom.com/articles/aging…

Mark Roithmayr (@theaddfceo) 's Twitter Profile Photo

An incredible night at the Inaugural ADDF Scientific Summit honoring Dan Skovronsky of Eli Lilly and Company with the 2025 Melvin R. Goodes Prize, the Nobel Prize of Alzheimer’s! Top researchers united & @DrSanjayGupta's inspiring talk with the determination to conquer Alzheimer’s!

An incredible night at the Inaugural ADDF Scientific Summit honoring Dan Skovronsky of <a href="/EliLillyandCo/">Eli Lilly and Company</a> with the 2025 Melvin R. Goodes Prize, the Nobel Prize of Alzheimer’s! Top researchers united &amp; @DrSanjayGupta's inspiring talk with the determination to conquer Alzheimer’s!
Mark Roithmayr (@theaddfceo) 's Twitter Profile Photo

Innovation drives the field forward. Great to see Fast Company recognize the innovation and technology @Alzpath, one of the Diagnostics Accelerator portfolio companies as one of the Most Innovative Biotech Companies of 2025!

Alzheimer's Drug Discovery Foundation (@theaddf) 's Twitter Profile Photo

A new study in The Lancet Neurology published on March 19, suggests early anti-amyloid drugs may prevent Alzheimer’s. WashU Medicine promising findings suggest early removal of the plaques before symptoms arise may delay or prevent the onset of AD. bit.ly/4hsnx7A

A new study in <a href="/TheLancetNeuro/">The Lancet Neurology</a> published on March 19, suggests early anti-amyloid drugs may prevent Alzheimer’s. <a href="/washumedicine/">WashU Medicine</a> promising findings suggest early removal of the plaques before symptoms arise may delay or prevent the onset of AD.

bit.ly/4hsnx7A
Alzheimer's Drug Discovery Foundation (@theaddf) 's Twitter Profile Photo

"There has never been a more exciting time to be in Alzheimer’s research.ā€ In a recent interview with pharmaboardroom, Mark Roithmayr discusses the need for innovative treatments and why ADDF’s venture philanthropy model is key to driving progress forward. bit.ly/4iMnXHn

Mark Roithmayr (@theaddfceo) 's Twitter Profile Photo

āø» I waited to post, honoring Leonard Lauder’s passing. Then Bill Gates shared this note on Alzheimer’s and the ADDF: šŸ”— people.com/5-years-after-… Leonard once told Bill: ā€œI’m too old to buy green bananas. Let’s start the Diagnostics Accelerator together.ā€ The rest is history.